HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (48) Citing Articles via Google Scholar Google Scholar Articles by Salvi, S. S. Articles by Holgate, S. T. Search for Related Content PubMed PubMed Citation Articles by Salvi, S. S. Articles by Holgate, S. T.

The Anti-inflammatory Effects of Leukotriene-Modifying Drugs and Their Use in Asthma^*

^* From the Respiratory Cell and Molecular Biology Division, Department of University Medicine, Southampton General Hospital, Southampton, UK.

Correspondence to: Sundeep S. Salvi, MD, PhD, Department of University Medicine, Level D Centre Block, Southampton General Hospital, Southampton SO16 6YD, UK; e-mail: sss{at}soton.ac.uk

Asthma is a chronic inflammatory disease of the airways. Anti-inflammatory drug therapy, primarily using corticosteroids, is now considered the first-line treatment in the management of all grades of asthma severity. Although corticosteroids are believed to be the most potent anti-inflammatory agents available, they do not suppress all inflammatory mediators involved in the asthmatic response. Leukotrienes, which are lipid mediators generated from the metabolism of arachidonic acid, play an important role in the pathogenesis of asthma. They produce bronchospasm, increase bronchial hyperresponsiveness, mucus production, and mucosal edema, and enhance airway smooth muscle cell proliferation and eosinophil recruitment into the airways, and their synthesis or release is unaffected by corticosteroid administration. The use of leukotriene synthesis inhibitors or leukotriene receptor antagonists as anti-inflammatory therapies in asthma has therefore been investigated. Beneficial effects of leukotriene-modifying drugs have been demonstrated in the management of all grades of asthma severity, and there is evidence that certain patient groups (such as those with exercise-induced asthma or aspirin-induced asthma) may be particularly suitable for such therapy.

Key Words: anti-inflammatory • antileukotrienes • aspirin-induced asthma • asthma • corticosteroids • eosinophil • inflammation

This article has been cited by other articles:

				M. Gaga, N. Papageorgiou, E. Zervas, D. Gioulekas, and S. Konstantopoulos Control of Asthma Under Specialist Care: Is It Achieved? Chest, July 1, 2005; 128(1): 78 - 84. [Abstract] [Full Text] [PDF]

				W. Busse and M. Kraft Cysteinyl Leukotrienes in Allergic Inflammation: Strategic Target for Therapy Chest, April 1, 2005; 127(4): 1312 - 1326. [Abstract] [Full Text] [PDF]

				D. A. Straub, A. Moeller, S. Minocchieri, J. Hamacher, F. H. Sennhauser, G. L. Hall, and J. H. Wildhaber The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma Eur. Respir. J., February 1, 2005; 25(2): 289 - 294. [Abstract] [Full Text] [PDF]

				F. Kanniess, K. Richter, S. Janicki, M.B. Schleiss, R.A. Jorres, and H. Magnussen Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Eur. Respir. J., November 1, 2002; 20(5): 1080 - 1087. [Abstract] [Full Text] [PDF]

				N. L. Dean Perimenstrual Asthma Exacerbations and Positioning of Leukotriene-Modifying Agents in Asthma Management Guidelines Chest, December 1, 2001; 120(6): 2116 - 2117. [Full Text] [PDF]

				K. Wedde-Beer, C. Hu, M. M. Rodriguez, and G. Piedimonte Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus Am J Physiol Lung Cell Mol Physiol, May 1, 2002; 282(5): L1143 - L1150. [Abstract] [Full Text] [PDF]

eLetters: